Diabetes drug holds promise for antipsychotic obesity

The diabetes drug exenatide may be a promising antidote to the weight gain commonly seen with antipsychotics such as clozapine, say psychiatrists.

Clozapine is the gold standard for treatment-refractory schizophrenia, but is associated with an average weight gain of 14kg over 10 years, which can deter patients.

A recent case report in the Australian and New Zealand Journal of Psychiatry suggests that doctors may be able to prevent this weight gain by prescribing exenatide (Byetta) to clozapine users.

The report describes an obese 43-year-old man who